Navigation Links
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
Date:12/9/2008

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of specific proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.

Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York, and Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation at Washington University School of Medicine, presented data from two ongoing Phase 2 clinical trials of carfilzomib in relapsed and refractory multiple myeloma patients during the Novel Therapies for Myeloma and Related Disorders oral session at the 50th Annual Meeting of the American Society of Hematology (ASH). Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC).

Activity in Relapsed and Refractory Multiple Myeloma Patients

Dr. Jagannath presented data from an ongoing, open-label, multi-center study of single-agent carfilzomib in multiple myeloma patients. All patients in this trial were refractory to their last treatment. Of 39 evaluable patients, ten (26%) achieved partial or minor responses and an additional 16 (41%) achieved stable disease. Importantly, responses have also been durable with median treatment duration of 240 days, or approximately eight months.

"Patients enrolled in this Phase 2 trial have previously failed bortezomib, lenalidomide, thalidomide, and stem cell transplant. Carfilzomib as a single-agent is well tolerated and has demonstrated encouraging a
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- The Alliance for Safe Biologic Medicines ... physicians at the "1 ST EuropaBio – ... the Spanish Ministry of Health, Social Services and ... Spanish Bioindustry Association (ASEBIO), included regulators from the ... and rheumatology societies, representatives from a hospital pharmacist ...
(Date:11/26/2014)... 2014 The ETC (Emerging Technology ... innovation centers, announced today that applications for AccelerateBaltimore™ ... 1st. “Do you have a big idea?,” asked ... to know about it. AccelerateBaltimore helps you and ... in just 13 weeks.” Interested game changers ...
(Date:11/26/2014)... Morristown, NJ (PRWEB) November 25, 2014 ... it has officially joined the Morris County (New ... MCCC, which is a leading business organization in ... unique opportunity to further engage some key clients ... have operations in the geographic area. Membership enables ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) provider ... , provider of clinical research and data management services ... to its CRO Partnership Program, Clinovo expands ClinCapture ... , “We have found Clinovo’s ClinCapture to exceed ... which is both user friendly and easy to deploy. ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2
... Fla. , Jan. 15 Andrew P. ... Foundation and diabetes advocate announced today that he will be ... a biotechnology company that has developed and patented a family ... and cosmetic industries. , "I,m really excited about their ...
... , Jan. 14 /PRNewswire-FirstCall/ - Medical International Technology Inc. ... that it has received clearance by FINRA to be traded on ... posted for trading on the OTC Bulletin Board at the opening ... MDLH.OB. , This is very positive news for all existing and ...
... ... Scholarships. The first is a two-year scholarship to be awarded to a graduating ... sponsor four scholarships for community-active, graduating Lake Braddock High School seniors. , ... Manassas, VA (PRWEB) January 13, ...
Cached Biology Technology:Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board 2MIT is pleased to announce that it has received clearance by FINRA to be listed on the OTC Bulletin Board "MDLH.OB" 2RiVIdium Inc. Creates Five Local Scholarships 2
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... and the Montreal Neurological Institute (MNI), McGill University have ... survival also play an active and major role in ... published this week in The Journal of Neuroscience ... variety of acute and chronic neurological disorders, including glaucoma ...
... impact on them caused by humanity,s carbon emissions. ... used coral from the Great Barrier Reef to reveal ... due to human activity. Professor Malcolm McCulloch, a ... Reef Studies and Australian National University today receives Australia,s ...
... (Nasdaq: AWRE ), a leading supplier of broadband ... first quarter ended March 31, 2009. Revenues for the ... 22% compared to $5.9 million in the same quarter last ... diluted net income per share in accordance with U.S. generally ...
Cached Biology News:Cell's split personality is a major discovery into neurological diseases 2Coral 'can't escape the heat' 2Aware, Inc. Reports First Quarter 2009 Financial Results 2Aware, Inc. Reports First Quarter 2009 Financial Results 3Aware, Inc. Reports First Quarter 2009 Financial Results 4Aware, Inc. Reports First Quarter 2009 Financial Results 5Aware, Inc. Reports First Quarter 2009 Financial Results 6
... Synthetic peptide derived from the C terminal ... This peptide sequence is downstream from ... polyclonal Connexin 36 antibody Cat. No. 51-6300. ... Reactivity: Mouse (positive control: mouse Connexin ...
...
...
...
Biology Products: